Ovarian cancer stem cell-specific gene expression profiling and targeted drug prescreening

Huang,Yuting; Ju,Baohui; Tian,Jing; Liu,Fenghua; Yu,Hu; Xiao,Huiting; Liu,Xiangyu; Liu,Wenxin; Yao,Zhi; Hao,Quan

doi:10.3892/or.2014.2976

Ovarian cancer stem cell-specific gene expression profiling and targeted drug prescreening

Authors:
- Yuting Huang
- Baohui Ju
- Jing Tian
- Fenghua Liu
- Hu Yu
- Huiting Xiao
- Xiangyu Liu
- Wenxin Liu
- Zhi Yao
- Quan Hao
View Affiliations

Affiliations: Department of Gynecological Oncology, Tianjin Medical Univerisity Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China, Department of Immunology, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Educational Ministry of China, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, P.R. China
Published online on: January 13, 2014 https://doi.org/10.3892/or.2014.2976
Pages: 1235-1248

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer stem cells, with unlimited self-renewal potential and other stem cell characteristics, occur in several types of cancer, including ovarian cancer (OvC). Although CSCs can cause tumor initiation, malignant proliferation, relapse and multi-drug resistance, ways to eliminate them remain unknown. In the present study, we compared ovarian cancer stem cell (OVCSC) expression profiles in normal ovarian surface epithelium and ovarian cells from patients with advanced disease to identify key pathways and specific molecular signatures involved in OVC progression and to prescreen candidate small-molecule compounds with anti-OVCSC activity. Comparison of genome-wide expression profiles of OvC stemness groups with non-stemness controls revealed 6495, 1347 and 509 differentially expressed genes in SDC, SP1 and SP2 groups, respectively, with a cut-off of fold-change set at >1.5 and P<0.05. NAB1 and NPIPL1 were commonly upregulated whereas PROS1, GREB1, KLF9 and MTUS1 were commonly downregulated in all 3 groups. Most differentially expressed genes consistently clustered with molecular functions such as protein receptor binding, kinase activity and chemo-repellent activity. These genes regulate cellular components such as centrosome, plasma membrane receptors, and basal lamina, and may participate in biological processes such as cell cycle regulation, chemoresistance and stemness induction. Key Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways such as ECM receptor, ErbB signaling, endocytosis and adherens junction pathways were enriched. Gene co-expression extrapolation screening by the Connectivity Map revealed several small-molecule compounds (such as SC-560, disulfiram, thapsigargin, esculetin and cinchonine) with potential anti-OVCSC properties targeting OVCSC signature genes. We identified several key CSC features and specific regulation networks in OVCSCs and predicted several small molecules with potential anti-OVCSC pharmacological properties, which may aid the development of OVCSC-specific drugs.

View Figures

View References

1	Dingli D and Michor F: Successful therapy must eradicate cancer stem cells. Stem Cells. 24:2603–2610. 2006. View Article : Google Scholar : PubMed/NCBI
2	Frank NY, Schatton T and Frank MH: The therapeutic promise of the cancer stem cell concept. J Clin Invest. 120:41–50. 2010. View Article : Google Scholar : PubMed/NCBI
3	Clarke-Pearson DL: Clinical practice. Screening for ovarian cancer. N Engl J Med. 361:170–177. 2009. View Article : Google Scholar : PubMed/NCBI
4	Zhang S, Balch C, Chan MW, et al: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68:4311–4320. 2008. View Article : Google Scholar : PubMed/NCBI
5	Rahman MT, Nakayama K, Rahman M, et al: Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer. Am J Clin Pathol. 138:535–544. 2012. View Article : Google Scholar : PubMed/NCBI
6	McAuliffe SM, Morgan SL, Wyant GA, et al: Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci USA. 109:E2939–E2948. 2012. View Article : Google Scholar : PubMed/NCBI
7	Gene Ontology Consortium. The Gene Ontology project in 2008. Nucleic Acids Res. 36:D440–D444. 2008.PubMed/NCBI
8	Kanehisa M, Goto S, Kawashima S, Okuno Y and Hattori M: The KEGG resource for deciphering the genome. Nucleic Acids Res. 32:D277–D280. 2004.PubMed/NCBI
9	Lamb J, Crawford ED, Peck D, et al: The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 313:1929–1935. 2006. View Article : Google Scholar
10	Lee JK, Havaleshko DM, Cho H, et al: A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA. 104:13086–13091. 2007. View Article : Google Scholar : PubMed/NCBI
11	Rizzo S, Hersey JM, Mellor P, et al: Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther. 10:325–335. 2011. View Article : Google Scholar : PubMed/NCBI
12	Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L and Birrer MJ: Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One. 7:e290792012. View Article : Google Scholar : PubMed/NCBI
13	Wang L, Mezencev R, Bowen NJ, Matyunina LV and McDonald JF: Isolation and characterization of stem-like cells from a human ovarian cancer cell line. Mol Cell Biochem. 363:257–268. 2012. View Article : Google Scholar : PubMed/NCBI
14	Bonome T, Levine DA, Shih J, et al: A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 68:5478–5486. 2008. View Article : Google Scholar : PubMed/NCBI
15	Ozols RF: Treatment goals in ovarian cancer. Int J Gynecol Cancer. 15(Suppl 1): 3–11. 2005. View Article : Google Scholar : PubMed/NCBI
16	Bapat SA, Mali AM, Koppikar CB and Kurrey NK: Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 65:3025–3029. 2005.PubMed/NCBI
17	Gotoh S, Nakamura T, Kataoka T and Taketani S: Egr-1 regulates the transcriptional repression of mouse δ-aminolevulinic acid synthase 1 by heme. Gene. 472:28–36. 2011.
18	Munksgaard PS and Blaakaer J: The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol. 124:164–169. 2012. View Article : Google Scholar : PubMed/NCBI
19	Grigo K, Wirsing A, Lucas B, Klein-Hitpass L and Ryffel GU: HNF4α orchestrates a set of 14 genes to down-regulate cell proliferation in kidney cells. Biol Chem. 389:179–187. 2008.
20	Hnatyszyn HJ, Liu M, Hilger A, et al: Correlation of GREB1 mRNA with protein expression in breast cancer: validation of a novel GREB1 monoclonal antibody. Breast Cancer Res Treat. 122:371–380. 2010. View Article : Google Scholar : PubMed/NCBI
21	Sahab ZJ, Man YG, Byers SW and Sang QX: Putative biomarkers and targets of estrogen receptor negative human breast cancer. Int J Mol Sci. 12:4504–4521. 2011. View Article : Google Scholar : PubMed/NCBI
22	Ying M, Sang Y, Li Y, et al: Kruppel-like family of transcription factor 9, a differentiation-associated transcription factor, suppresses Notch1 signaling and inhibits glioblastoma-initiating stem cells. Stem Cells. 29:20–31. 2011. View Article : Google Scholar
23	Ding X, Zhang N, Cai Y, et al: Down-regulation of tumor suppressor MTUS1/ATIP is associated with enhanced proliferation, poor differentiation and poor prognosis in oral tongue squamous cell carcinoma. Mol Oncol. 6:73–80. 2012. View Article : Google Scholar : PubMed/NCBI
24	Tan DS, Lambros MB, Rayter S, et al: PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res. 15:2269–2280. 2009. View Article : Google Scholar : PubMed/NCBI
25	Ali AY, Abedini MR and Tsang BK: The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. Oncogene. 31:2175–2186. 2012. View Article : Google Scholar : PubMed/NCBI
26	Paolella BR, Havrda MC, Mantani A, Wray CM, Zhang Z and Israel MA: p53 directly represses Id2 to inhibit the proliferation of neural progenitor cells. Stem Cells. 29:1090–1101. 2011. View Article : Google Scholar : PubMed/NCBI
27	Krupp M, Maass T, Marquardt JU, et al: The functional cancer map: a systems-level synopsis of genetic deregulation in cancer. BMC Med Genomics. 4:532011. View Article : Google Scholar : PubMed/NCBI
28	Lane D, Goncharenko-Khaider N, Rancourt C and Piche A: Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene. 29:3519–3531. 2010.
29	Nakanishi T, Chumsri S, Khakpour N, et al: Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer. 102:815–826. 2010. View Article : Google Scholar : PubMed/NCBI
30	Hardy KM, Booth BW, Hendrix MJ, Salomon DS and Strizzi L: ErbB/EGF signaling and EMT in mammary development and breast cancer. J Mammary Gland Biol Neoplasia. 15:191–199. 2010. View Article : Google Scholar : PubMed/NCBI
31	Wang KH, Kao AP, Chang CC, et al: Increasing CD44⁺/CD24⁻ tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis. Mol Cancer. 9:2882010.
32	Katoh M and Katoh M: STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (Review). Int J Mol Med. 19:273–278. 2007.PubMed/NCBI
33	Bronowski C, Smith SL, Yokota K, et al: A subset of mucosa-associated Escherichia coli isolates from patients with colon cancer, but not Crohn’s disease, share pathogenicity islands with urinary pathogenic E. coli. Microbiology. 154:571–583. 2008.PubMed/NCBI
34	Bourseau-Guilmain E, Griveau A, Benoit JP and Garcion E: The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells. PLoS One. 6:e255152011. View Article : Google Scholar : PubMed/NCBI
35	Wu WK, Sung JJ, Wu YC, et al: Inhibition of cyclooxygenase-1 lowers proliferation and induces macroautophagy in colon cancer cells. Biochem Biophys Res Commun. 382:79–84. 2009. View Article : Google Scholar : PubMed/NCBI
36	Li W, Wang J, Jiang HR, et al: Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo. Int J Mol Sci. 12:668–681. 2011. View Article : Google Scholar : PubMed/NCBI
37	Silva IA, Bai S, McLean K, et al: Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 71:3991–4001. 2011. View Article : Google Scholar : PubMed/NCBI
38	Kast RE and Belda-Iniesta C: Suppressing glioblastoma stem cell function by aldehyde dehydrogenase inhibition with chloramphenicol or disulfiram as a new treatment adjunct: an hypothesis. Curr Stem Cell Res Ther. 4:314–317. 2009. View Article : Google Scholar : PubMed/NCBI
39	Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA and Darwiche N: What made sesquiterpene lactones reach cancer clinical trials? Drug Discov Today. 15:668–678. 2010. View Article : Google Scholar : PubMed/NCBI
40	Park SS, Park SK, Lim JH, Choi YH, Kim WJ and Moon SK: Esculetin inhibits cell proliferation through the Ras/ERK1/2 pathway in human colon cancer cells. Oncol Rep. 25:223–230. 2011.PubMed/NCBI
41	Nakamura Y: Retracted: Modulation of p53/Akt/phosphatase and tensin homolog expression by esculetin potentiates the anticancer activity of cisplatin and prevents its nephrotoxicity. Cancer Sci. 103:1542012. View Article : Google Scholar : PubMed/NCBI
42	Furusawa S, Nakano S, Wu J, et al: Apoptosis induced by doxorubicin and cinchonine in P388 multidrug-resistant cells. J Pharm Pharmacol. 53:1029–1039. 2001. View Article : Google Scholar : PubMed/NCBI
43	Lee SY, Rhee YH, Jeong SJ, et al: Hydrocinchonine, cinchonine, and quinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/DX5 uterine sarcoma cells. Environ Toxicol. 26:424–431. 2011. View Article : Google Scholar
44	Donahue RN, McLaughlin PJ and Zagon IS: Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med (Maywood). 236:883–895. 2011. View Article : Google Scholar : PubMed/NCBI
45	Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV and Varticovski L: Brca1 breast tumors contain distinct CD44⁺/CD24⁻ and CD133⁺ cells with cancer stem cell characteristics. Breast Cancer Res. 10:R102008. View Article : Google Scholar
46	Sauvageot CM, Weatherbee JL, Kesari S, et al: Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol. 11:109–121. 2009. View Article : Google Scholar : PubMed/NCBI
47	Tatokoro M, Koga F, Yoshida S, et al: Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. Int J Cancer. 131:987–996. 2012. View Article : Google Scholar : PubMed/NCBI
48	Yip NC, Fombon IS, Liu P, et al: Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer. 104:1564–1574. 2011.PubMed/NCBI